JNJ | Weekly | Haru Insights

Johnson & Johnson received FDA approval for Imaavy (nipocalimab-aahu) as the first-in-class treatment for warm autoimmune hemolytic anemia (wAIHA), marking a transformative regulatory milestone with immediate commercial and strategic implications.
JNJ secured Chinese approval for Icotyde, its oral IL-23 inhibitor for psoriasis, signaling a pivotal expansion into the high-growth oral therapy segment and a direct challenge to injectable competitors like Skyrizi and Tremfya.

JNJ’s FDA approval of Imaavy is a game-changing validation of its rare disease immunology platform, establishing the company as a first-mover in a high-margin niche with $5 billion+ peak sales potential.
The successful launch of Icotyde in China could redefine JNJ’s immunology growth trajectory by capturing market share from injectables through patient-friendly oral dosing in a massive patient pool.
Icotyde’s approval in China reflects JNJ’s expanding global commercial reach, particularly in a market where oral biologics are gaining rapid adoption, underscoring its R&D agility and market responsiveness.
Imaavy’s first-in-class status in wAIHA delivers a rare regulatory win in the rare disease space, enhancing JNJ’s reputation as an innovator and strengthening its pipeline credibility.
The dual momentum from Imaavy and Icotyde demonstrates JNJ’s ability to execute on both ultra-niche and broad-market immunology strategies, reinforcing its portfolio diversification and long-term resilience.

Johnson & Johnson (JNJ)[Tv]